• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

April 24, 2013

View Archived Issues

Avalon, GSK Deal: Start 10 New Firms via Mutual Cash Outlay

CHICAGO – A week after he talked with BioWorld Today about his success in helping pharmaceutical firms backfill their dwindling pipelines with promising, early stage deals, Avalon Ventures partner Jay Lichter disclosed a multi-company arrangement designed to do just that in a big way for GlaxoSmithKline plc. Read More

Orphan Drugs Continue to Captivate Industry's Attention

CHICAGO – It wasn't all that long ago that orphan drugs were considered too small to devote valuable R&D resources on. As a consequence, they did not feature prominently on the product development radar screens of pharma or biotech companies. Read More

Easing the Burden of HCV Treatment at EASL 2013

Clinical trials marking progress toward a broad-acting, all-oral regimen for treating hepatitis C were reported in The New England Journal of Medicine and at the International Liver Congress of the European Association for the Study of the Liver (EASL) in Amsterdam, the Netherlands, this week. Read More

Pharmas, Academia Seek to Bridge the Great Divide

CHICAGO – Small biotechs, already smarting from the stingy venture capital (VC) market and cutbacks in government funding, are looking nervously over their shoulder at the increasingly cozy relationship between big pharmas and academic institutions. And well they should. Read More

BioPeople: aTyr's Mendlein Keeps Sights on New Biology

CHICAGO – John Mendlein may not look like the typical biotech exec – the long hair and laid-back manner suggest he might be more at home catching a few waves rather than moderating a panel on orphan and rare diseases, as he did Tuesday morning at the BIO 2013 International Convention. Read More

Biopharma Finding Value in Companion Diagnostics

CHICAGO – While companion diagnostics have been an aspirational goal for the biotech industry for a number of years, the development pipeline has been held up by strategic and technical pitfalls. Read More

Stock Movers

Read More

Adcom Survival Guide: Prep, Practice and Get to the Point

CHICAGO – Getting through an FDA advisory committee is an oft-dreaded rite of passage for developers of novel drug candidates, and stories of disastrous adcoms have a tendency to circulate around the biopharma industry like urban myths. Read More

TiGenix Stem Cell Therapy Helps Refractory RA Patients

LONDON – TiGenix NV unveiled positive Phase IIa results for its Cx611 allogeneic stem cell therapy in the treatment of 53 rheumatoid arthritis patients whose disease was not responsive to disease-modifying anti-rheumatic drugs (DMARDS) or biologics. Read More

Financings Roundup

• iBio Inc., of Newark, Del., priced a public offering of 8.925 million units at 48 cents each raising about $4.28 million. Each unit consists of one share of common stock and 0.4 of a warrant to purchase one share, with an exercise price of 53 cents per share. Read More

Earnings Roundup

• Ironwood Pharmaceuticals Inc., of Cambridge, Mass., said it ended the first quarter with $242 million in cash, cash equivalents and securities, using about $93 million in net cash for operations. Read More

Clinic Roundup

• Advanced Cell Technology Inc., of Marlborough, Mass., said the first subject in the third dosage cohort was injected with 150,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells in its European Phase I trial for Stargardt's macular dystrophy (SMD). Read More

Other News To Note

• NanoBio Corp., of Ann Arbor, Mich., said its intramuscular nanoemulsion-adjuvanted respiratory syncytial virus vaccine was safe and highly effective in protecting cotton rats against RSV without causing enhanced disease. Read More

Pharma: Other News To Note

• Sucampo Pharmaceuticals Inc., of Bethesda, Md., said the FDA approved its prostone-based therapy Amitiza (lubiprostone) as the first oral treatment of opioid-induced constipation (OIC) in patients with chronic, noncancer pain. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 13, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 13, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe